Hepatitis B and C Surface Antigens and Typhoid Fever in Voluntary Non – Remunerated Blood Donors in Abakaliki, Nigeria
European Journal of Clinical and Biomedical Sciences
Volume 5, Issue 1, February 2019, Pages: 9-15
Received: Feb. 14, 2019; Accepted: Mar. 21, 2019; Published: Apr. 22, 2019
Views 70      Downloads 16
Unah Victor Unah, Department of Microbiology, University of Nigeria, Nsukka, Nigeria
Eze Emmanuel Aniebonam, Department of Microbiology, University of Nigeria, Nsukka, Nigeria
Lerum Nathaniel Isaiah, Department of Microbiology, University of Nigeria, Nsukka, Nigeria
Egbe Kingsley Andrew, Department of Microbiology, University of Nigeria, Nsukka, Nigeria
Article Tools
Follow on us
Infections due to Hepatitis B and Hepatitis C Viruses (HBV and HCV) are worldwide significant problems in public health. This cross-sectional and comparative study was carried out to evaluate and compare the prevalence of HBV, HCV and typhoid bacteria among voluntary non-remunerated blood donors in Abakaliki, Nigeria. A total of 307 voluntary non-remunerated blood donors were screened using rapid test (Global Rapid Diagnostic Kit, USA) for the detection of HBsAg and anti-HCV in serum samples. The positive samples were screened using ELISA Kit (Clinotech Diagnostics, Canada) to check the specificity of the screening test for HBV and HCV. The results obtained showed that 20(6.52%) and 10(3.26%) were seropositive to HBsAg and anti-HCV respectively. The prevalence of HBsAg and HCV were higher in males 17(5.54%) and 6(1.95%) compared to 3(0.98%) and 4(1.30%) in females respectively. Age specific prevalence of HBV was higher in the age brackets 15-24 and 25-34 years with 4(6.67%), and 14(8.33%), lower in the age bracket 35-44 with 2(2.70%) and lowest in the age bracket 45+ years with 0(0.00%). Age specific prevalence of HCV was higher in the age brackets 25-34 and 35-44 years with 7(4.17%) and 3(4.05%) respectively and lowest in the age brackets 15-24 and 45+ years with no cases at all among them. Statistically, there was no significant relationship between age, HBV and HCV infections (p > 0.05). The most important risk factors in the acquisition of HBsAg as revealed in this study appears to be: those with multiple sexual partners, 12(20.00%), family history of hepatitis, 4(15.39%), blood transfusion 5(9.62%), and tribal mark/tattooing, 2(6.25%) while the most important risk factors in the acquisition of HCV appears to be: family history of hepatitis, 5(19.23%), and blood transfusion 4(7.69%). In comparison, HBV is more prevalent among blood donors in Abakaliki than HCV. Furthermore, this study also reveals that few blood donors have bacteraemia, thus the prevalence of typhoid bacteria among blood donors is very low. The intermediate prevalence of HBV and HCV, and low prevalence of typhoid bacteria recorded among blood donors in this study are probably a reflection of situation in Abakaliki, Nigeria. Therefore, urgent-preventive measures should be taken to set up campaign against transmission of HBV and HCV in Abakaliki, Nigeria. To lower hepatitis prevalence, program of active screening and vaccination for voluntary non-remunerated blood donors is recommended.
HBV, HCV, Typhoid Bacteria, Voluntary Non-Remunerated, Blood Donor
To cite this article
Unah Victor Unah, Eze Emmanuel Aniebonam, Lerum Nathaniel Isaiah, Egbe Kingsley Andrew, Hepatitis B and C Surface Antigens and Typhoid Fever in Voluntary Non – Remunerated Blood Donors in Abakaliki, Nigeria, European Journal of Clinical and Biomedical Sciences. Vol. 5, No. 1, 2019, pp. 9-15. doi: 10.11648/j.ejcbs.20190501.13
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ryder, S. D. and Beckingham, I. J. (2001). ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis. British Medical Journal Clinical Research; 322 (7279): 151 - 153.
Ahmedin, J., Taylor, M. and Ram, C. T. (2004). A new section in cancer offering timely and targeted information. Canadian Journal of Clinical Medicine, 54: 23-25.
Ahmed, I., Khan, S. B., Rahman, H. U., Khan, M. H. and Anwar, S. (2006). Frequency of hepatitis B and hepatitis C among cataract patients. Gomal Journal of Medical Science, 4: 61-64.
Mohammed, J., Hussain, M. and Khan, M. A. (2003). Frequency of hepatitis B and hepatitis C infection in thalassaemic children. Pakistanian Paediatrist Journal. 27:161 - 164.
Ahmad, K. (1998). Hepatitis B in viral hepatitis: An overview: Proceedings of seminar. AFIP Rawalpindi, Pakistan, 16-19.
Schiff, E. (2002). Hepatitis central, current information on hepatitis C and treatment for medical profession. University of Miami; 1 - 2.
Cheesbrough, M. (2006). District laboratory practice in tropical countries part 1 and 2. Cambridge University Press, United Kingdom.
Clinical and Laboratory Standard Institute. (2014). Performance standard for antimicrobial susceptibility testing; 24th informational supplement M100 S24, 34 (1). Clinical and Laboratory Standard Institute, Wayne, PA 19087 USA.
Zaller, N., Nelson, K. E., Aladashvili M., Badridze N., del Rio, C. and Tsertvadze T. (2004). Risk factors for hepatitis C virus infection among blood donors in Georgia. European Journal of Epidemiology, Netherlands, 19 (6): 547- 553.
[10] Lok, A. S. F. (2002). Chronic hepatitis B. New England Journal of Medicine, 346: 1682-1683.
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H. W. L., Goodman Z., Crowther, L., Condreay, L. D., Woessner, M. Rubin, M., and Brown, N. A. (1999). Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine, 341 (17): 1256-1263.
Craig, S. (1999). Epidemiology of hepatitis B. The paediatric infectious Disease Journal, 12 (5): 433-436.
Alter, M. J., Kruszon-Moran, D., Nainan, D. V., McQuillan, G. M., Gao, F., Moyer, L. A., kaslow, R. A. and Margolis, H. S. (1988). The prevalence of hepatitis C virus infection in the US, 1988 through 1994. England Journal of medicine, 341 (8):556-562.
Carrosco, D. A., Newman, C. and Tyring, S. K. (1998). Treatment of viral hepatitis. Harrison’s principles of internal medicine 14th edition, 2: 1677-1692.
Greenberyer, N. J. (1995). Hepatitis C: More common than suspected. Clinical focus, 18-24.
Pennap, G. R., Yakubu, A., Oyige, O. and Forbi, J. (2010). Prevalence of hepatitis B and C virus infection among people of a local community in Keffi, Nigeria. African Journal of Microbiology Research, 4 (4): 274-278.
Tanfer, K., Cubbins, A. L. and Billy, J. O. (1995). Gender, race, class and self-reported sexually transmitted disease incidence. Fam. Plann. Perspect. 27 (5): 196-202.
Otegbayo, Y. A., Fasola, F. O. and Abaja, A. (2003). Prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B envelop antigens (HBeAg), risk factors of viral acquisition and transaminase among blood donors in Ibadan, Nigeria. Tropical Gastroenterology. 24: 217 -226.
Uneke, C. J., Ogbu, O., Inyama, P. U., Anyanwu, G. I., Njoku, M. O. and Idoko, J. H. (2005). Prevalence of Hepatitis B surface antigen among blood donors and human Immunodeficiency virus-infected Patients in Jos, Nigeria. Mem Inst Oswaldo Cruz. 100 (1): 13 -16.
Hollinger, F. B. and Liang, T. J. (2001). Hepatitis B virus. Fields virology, 4th ed. Philadelphia, Lippincott Williams and Wilkins, 2971-3036.
Viral Hepatitis Prevention Board. (1996). The clock is running, 1997: deadline for integrating hepatitis B vaccinations into all national immunization programs. Fact Sheet VHPB/ 1996/1.
UNSN. (2001). Nigeria Born Mon Country Assessment World Health Organization Geneva, pp 563.
Alter, M. J. (2003). Epidemiology of hepatitis B in Europe and worldwide. Journal of hepatology. 39: S64 - S69.
Ivanoff, B., Cordell, J. and Robert, O. and Fontanges, R. (1980). Importance de la voice respiratoire dan la Salmonellose experimentale de la souris Balble. Comptes Rendus de l’ Academic des sciences (paris), 1271- 1274.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186